

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 66161

Title: Primary gastric non-Hodgkin lymphomas: Recent advances regarding disease

pathogenesis and treatment

Reviewer's code: 02536364 Position: Peer Reviewer Academic degree: MD, PhD

Professional title: Doctor

Reviewer's Country/Territory: Japan

Author's Country/Territory: Greece

Manuscript submission date: 2021-03-22

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-03-22 10:46

Reviewer performed review: 2021-03-26 03:59

Review time: 3 Days and 17 Hours

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[Y]Yes []No
Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous
statements	Conflicts-of-Interest: [] Yes [Y] No



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

E-mail: bpgoffice@wjgnet.com **https:**//www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

This paper is a review article of gastric DLBCL and MALT lymphomas, which describe recent advances in their pathogenesis and treatment. Among the numerous papers on the gastric DLBCL and MALT lymphomas, the author(s) has selected the necessary articles suitable for discussing recent advances in their pathogenesis and treatment and explained them from his own perspective. Gastric DLBCL is a heterogeneous disease that is actually difficult to review, and I would like to pay tribute to the author(s) who compiled this educational review article. Well, there is one thing I would like to confirm with the author(s). H. pylori eradication has already been established for gastric MALT lymphoma, but do you think it is also effective for DLBCL? Only one line is mentioned in this paper with one article as a reference, but I wanted you to comment a little deeper. (The below paper also reported the effectiveness of H. pylori eradication for gastric DLBCL.) Even recently, there have been reports of successes and failures, and it seems that opinions are divided, so please tell us your thoughts. Finally, I highly appreciate this paper, and I hope that this article will be accepted with only a few revisions. Paydas S. Helicobacter pylori eradication in gastric diffuse large B cell lymphoma. World J Gastroenterol. 2015 Apr 7;21(13):3773-6. doi: 10.3748/wjg.v21.i13.3773. PMID: 25852262



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 66161

Title: Primary gastric non-Hodgkin lymphomas: Recent advances regarding disease

pathogenesis and treatment

Reviewer's code: 05252929 Position: Peer Reviewer Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: United States

Author's Country/Territory: Greece

Manuscript submission date: 2021-03-22

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-03-25 23:32

Reviewer performed review: 2021-03-26 19:03

Review time: 19 Hours

Scientific quality	[] Grade A: Excellent [] Grade B: Very good [] Grade C: Good [Y] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [Y] Minor revision [] Major revision [] Rejection
Re-review	[Y]Yes []No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

Very elaborate. Few things I suggest: 1. Benefit of CHOP vs R-CHOP therapy and checkpoint inhibitors can be given in a table so that it will be easy for the readers to understand. 2. Role of radiation in primary gastric DLBCL and gastric MALToma not mentioned at all.



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 66161

Title: Primary gastric non-Hodgkin lymphomas: Recent advances regarding disease

pathogenesis and treatment

Reviewer's code: 05914495 Position: Peer Reviewer Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: Greece

Manuscript submission date: 2021-03-22

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-03-24 07:56

Reviewer performed review: 2021-04-02 08:09

Review time: 9 Days

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [] Minor revision [Y] Major revision [] Rejection
Re-review	[Y]Yes []No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

1. In the molecular pathogenesis, please check the spell of immune-pirivileged in the fifth row. 2. In my opinion, authors should add references as a review. 3. It is difficult for reviewer to point out the problem in the absence of line number. 4. An additional list of acronyms is more readable. 5. Insufficient evidence is listed to support immunochemotherapy (R-CHOP) is the optimal treatment for patients with DLBCL PGLs. 6. In the part of clinical studies, I don't understand what authors expressed in the first paragraph.